Neuronetics, Inc. Q3 2025 Earnings Recap

STIM Q3 2025 November 4, 2025

Get alerts when STIM reports next quarter

Neuronetics reported a strong Q3 2025, with total revenue increasing 11% year-over-year, driven by robust performance in Greenbrook clinics and effective integration strategies.

Earnings Per Share Miss

$-0.13 vs $-0.12 est.

-8.3% surprise

Revenue Miss

37297000 vs 37846000 est.

-1.5% surprise

Market Reaction

1-Day +3.61%

5-Day -17.69%

30-Day -47.65%

See STIM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue reached $37.3 million, bolstered by a 25% increase in revenue at Greenbrook clinics.
System sales for NeuroStar were solid, with 40 units shipped and consistent average selling prices exceeding targets.
Treatment session utilization for NeuroStar grew by 11% compared to the prior year, indicating strong demand for its services.
The underway integration of the Greenbrook business and expansion of the SPRAVATO rollout is poised to enhance operational efficiency and profitability.
The company strategically optimized its RAM program, successfully scheduling over 350 physician meetings to drive referrals, resulting in over 2,200 patients referred in Q3.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit STIM on AllInvestView.